Vitamin K-dependent procoagulant in cancer cells: a potential target for the antimetastatic effect of warfarin?
Anticoagulants of the coumarin type have long been reported to inhibit metastasis growth in experimental animals; however, the mechanisms of such effects has not been clarified. Systemic anticoagulation per se does not appear to account completely for such metastasis growth depression. More recent information gathered on a cell procoagulant activity, which is vitamin K-dependent, could probably supply a fresh insight into this problem. Indeed, vitamin K deficiency induced either dietarily or pharmacologically by warfarin, does inhibit the activity of a cysteine protease with direct factor-X-activating properties. This protease is only present in warfarin-sensitive tumors. The correlation of this activity with cancer cell invasiveness is supported by experimental data in metastatic variants and, lately, also by the observation of markedly higher cancer procoagulant activity in extracts from metastases than from primary human melanomas.
D000818:Animals; D000970:Antineoplastic Agents; D001779:Blood Coagulation Factors / Q000378:metabolism; D003546:Cysteine Endopeptidases; D010450:Endopeptidases / Q000378:metabolism*; D006801:Humans; D009362:Neoplasm Metastasis / Q000503:physiopathology; D009363:Neoplasm Proteins; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D011480:Protease Inhibitors; D014812:Vitamin K / Q000378:metabolism; D014859:Warfarin / Q000494:pharmacology*
D000970:Antineoplastic Agents; D001779:Blood Coagulation Factors; D009363:Neoplasm Proteins; D011480:Protease Inhibitors; D014812:Vitamin K; D014859:Warfarin; D010450:Endopeptidases; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant